Related Experiment Video
Updated: May 18, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Left ventricular assist for high-risk percutaneous coronary intervention
Haile A Jones1, Deepika R Kalisetti, Mahender Gaba
1Cardiology Consultants of Philadelphia, Hahnemann University Hospital, 230 North Broad MS108, Philadelphia, Pennsylvania 19102, USA.
Percutaneous coronary intervention (PCI) for high-risk patients involves assist devices to reduce risk. Evidence does not clearly favor more invasive devices over the intra-aortic balloon pump (IABP).
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
Background:
- Percutaneous coronary intervention (PCI) is increasingly used in high-risk patients, including those with complex coronary artery disease and impaired cardiac function.
- Various percutaneous assist devices have been employed to mitigate procedural risks in these challenging cases.
Purpose of the Study:
- To review the physiological mechanisms of percutaneous assist devices used during high-risk PCI.
- To discuss the indications, limitations, and clinical outcomes associated with these devices.
Main Methods:
- Literature review of studies on percutaneous assist devices in high-risk PCI.
- Analysis of physiological mechanisms, clinical indications, limitations, and outcomes.
Main Results:
- No definitive evidence supports the superiority of more invasive assist devices over the intra-aortic balloon pump (IABP).
- Prophylactic IABP insertion has not demonstrated superiority over a provisional strategy.
Conclusions:
- The optimal use of percutaneous assist devices in high-risk PCI requires careful consideration of individual patient factors and device-specific evidence.
- Further research is needed to establish clear guidelines for device selection and strategy in complex PCI procedures.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
